Pierre Bourdillon1,2,3,4, Jean Isnard5,6, Hélène Catenoix5, Alexandra Montavont5,7, Sylvain Rheims2,5,6, Philippe Ryvlin6,8, Karine Ostrowsky-Coste7, François Mauguiere2,5,6, Marc Guénot1,2,6. 1. Department of Neurosurgery, Hospices Civils de Lyon (Lyon University Hospital), Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France. 2. Lyon University, Claude Bernard University, Lyon, France. 3. Brain and Spine Institute, INSERM U1127, CNRS 7225, Paris, France. 4. Sorbonne University, Pierre and Marie Curie University, Paris, France. 5. Department of Functional Neurology and Epileptology, Hospices Civils de Lyon (Lyon University Hospital), Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France. 6. Neuroscience Research Center of Lyon, INSERM U1028, CNRS 5292, Lyon, France. 7. Department of Pediatric Clinical Neurophysiology, Hospices Civils de Lyon (Lyon University Hospital), Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France. 8. Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland.
Abstract
OBJECTIVE: Stereo electroencephalography (SEEG)-guided radiofrequency thermocoagulation (SEEG-guided RF-TC) has been proposed since 2004 as a possible treatment of some focal drug-resistant epilepsy. The aim of this study is to provide extensive data about efficacy and safety of SEEG-guided RF-TC. METHODS: Over a 10-year period, 162 patients with drug-resistant focal epilepsy were eligible for SEEG-guided RF-TG during phase II invasive investigation by SEEG. All follow-up and safety data were collected prospectively. The primary outcome was seizure freedom at 2 months and at 1 year after SEEG-guided RF-TC. Secondary outcomes were the responders' rate (patient with at least 50% decrease in seizure frequency) and their long-term follow-up. RESULTS: Twenty-five percent of patients were seizure-free at 2 months and 7% at 1 year. We reported 67% of responders at 2 months and 48% at 1 year; 58% of responders maintained their status during the long-term follow-up. The seizure outcome was significantly better when the SEEG-guided RF-TC involved the occipital region (p = 0.007). When surgery followed an SEEG-guided RF-TC, the positive predictive value of being a responder 2 months after an SEEG-guided RF-TC and to be Engel's class I or II after surgery was 93%. We reported 1.1% of permanent deficit and 2.4% of transient side effects. SIGNIFICANCE: Our results, gathered in a large population over a 10-year period, confirm that SEEG-guided RF-TC is a safe technique, being efficient in many cases. More than two thirds of patients showed a short-term improvement, and almost half of them were responders at 1-year follow-up. The technique appears to be especially interesting for limited epileptic zone inaccessible to surgery and when epilepsy is related to a large unilateral network (network disruption by multiple RF-TC). Furthermore, SEEG-guided RF-TC effect is a predictor of outcome after conventional cortectomy in patients eligible for surgery. Wiley Periodicals, Inc.
OBJECTIVE: Stereo electroencephalography (SEEG)-guided radiofrequency thermocoagulation (SEEG-guided RF-TC) has been proposed since 2004 as a possible treatment of some focal drug-resistant epilepsy. The aim of this study is to provide extensive data about efficacy and safety of SEEG-guided RF-TC. METHODS: Over a 10-year period, 162 patients with drug-resistant focal epilepsy were eligible for SEEG-guided RF-TG during phase II invasive investigation by SEEG. All follow-up and safety data were collected prospectively. The primary outcome was seizure freedom at 2 months and at 1 year after SEEG-guided RF-TC. Secondary outcomes were the responders' rate (patient with at least 50% decrease in seizure frequency) and their long-term follow-up. RESULTS: Twenty-five percent of patients were seizure-free at 2 months and 7% at 1 year. We reported 67% of responders at 2 months and 48% at 1 year; 58% of responders maintained their status during the long-term follow-up. The seizure outcome was significantly better when the SEEG-guided RF-TC involved the occipital region (p = 0.007). When surgery followed an SEEG-guided RF-TC, the positive predictive value of being a responder 2 months after an SEEG-guided RF-TC and to be Engel's class I or II after surgery was 93%. We reported 1.1% of permanent deficit and 2.4% of transient side effects. SIGNIFICANCE: Our results, gathered in a large population over a 10-year period, confirm that SEEG-guided RF-TC is a safe technique, being efficient in many cases. More than two thirds of patients showed a short-term improvement, and almost half of them were responders at 1-year follow-up. The technique appears to be especially interesting for limited epileptic zone inaccessible to surgery and when epilepsy is related to a large unilateral network (network disruption by multiple RF-TC). Furthermore, SEEG-guided RF-TC effect is a predictor of outcome after conventional cortectomy in patients eligible for surgery. Wiley Periodicals, Inc.
Authors: John P Andrews; Abhijeet Gummadavelli; Pue Farooque; Jennifer Bonito; Christopher Arencibia; Hal Blumenfeld; Dennis D Spencer Journal: JAMA Neurol Date: 2019-04-01 Impact factor: 18.302
Authors: Pierre Bourdillon; S Ferrand-Sorbet; C Apra; M Chipaux; E Raffo; S Rosenberg; C Bulteau; N Dorison; O Bekaert; V Dinkelacker; C Le Guérinel; M Fohlen; G Dorfmüller Journal: Neurosurg Rev Date: 2020-04-21 Impact factor: 3.042
Authors: Andreas Koupparis; Nicolás von Ellenrieder; Hui Ming Khoo; Natalja Zazubovits; Dang Khoa Nguyen; Jeffery A Hall; Roy W R Dudley; Francois Dubeau; Jean Gotman Journal: Neurology Date: 2021-08-16 Impact factor: 11.800